" class="no-js "lang="en-US"> Ionis - Medtech Alert
Friday, April 12, 2024

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Ionis | PTF

Ionis

About Ionis

Ionis
For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision to become the leader in genetic medicine, utilizing a multi-platform approach to discover, develop and deliver life-transforming therapies.

Related Story

Clinical Trials

 Eplontersen Halted ATTRv-PN Disease Progression and Improved Neuropathy Impairment and Quality of Life in Study | MTA

Eplontersen Halted ATTRv-PN Disease Progression and Improved Neuropathy Impairment and Quality of Life in Study

April 25 2023

Ionis Pharmaceuticals today announced that the Phase 3 NEURO-TTRansform study for AstraZeneca and Ionis’ eplontersen […]

Diseases

 Ionis Accounces FDA Advisory Committee Voted Unanimously for a Potential Accelerated Approval of Tofersen for SOD1-ALS | MTA

Ionis Accounces FDA Advisory Committee Voted Unanimously for a Potential Accelerated Approval of Tofersen for SOD1-ALS

March 23 2023

Ionis has announced the outcome of the United States Food and Drug Administration’s (FDA) Peripheral […]

Diseases

 Ionis receives FDA Fast Track designation for Olezarsen in patients with Familial Chylomicronemia Syndrome | PTF

Ionis receives FDA Fast Track designation for Olezarsen in patients with Familial Chylomicronemia Syndrome

January 31 2023

Ionis Pharmaceuticals today announced that the United States Food and Drug Administration (FDA) has granted […]

News

 Ionis and Royalty Pharma Enter Into Royalty Agreement for Up to $1.1 billion | PTF

Ionis and Royalty Pharma Enter Into Royalty Agreement for Up to $1.1 billion

January 9 2023

Ionis Pharmaceuticals and Royalty Pharma plc today announced that Royalty Pharma has acquired an interest […]